

Product Data Sheet

Product Name: Pentoxifylline-d6

Cat. No.: GC48829

Chemical Properties

Cas. No. 1185879-03-1

SMILES O=C1C2=C(N=CN2C([2H])([2H])[2H])N(C(N1CCCCC(C)=O)=O)C([2H])([2H])[2H]


Formula C₁₃H₁₂D₆N₄O₃ M.Wt 284.3

Solubility DMSO : ≥ 10 mg/mL (35.17 mM); Storage -20°C
DMF : ≥ 10 mg/mL (35.17 mM);
Ethanol : ≥ 2 mg/mL (7.03 mM); PBS
(pH 7.2) : ≥ 1 mg/mL (3.52 mM)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

Pentoxifylline-d₆ is intended for use as an internal standard for the quantification of pentoxifylline by GC- or LC-MS. Pentoxifylline is a hemorrheologic agent.¹ It increases the deformability of washed isolated human erythrocytes when used at a concentration of 100 μM.² Pentoxifylline (1, 2, and 3 mM) inhibits ADP-induced platelet aggregation in isolated human whole blood.³ It inhibits thrombus formation induced by ADP in a hamster cheek pouch model when administered at doses of 5, 10, and 20 mg/kg.⁴ Formulations containing pentoxifylline have been used in the treatment of intermittent claudication.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

1. Ward, A., and Clissold, S.P. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy *Drugs* 34(1)50-97(1987) 2. S?oczyńska, K., KÓzka, M., P?kala, E., et al. In vitro effect of pentoxifylline and lisofylline on deformability and aggregation of red blood cells from healthy subjects and patients with chronic venous disease *Acta Biochim. Pol.* 60(1)129-135(2013) 3. Magnusson, B., Gunnarsson, M., Berntorp, E., et al. Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans *Eur. J. Pharmacol.* 581(3)290-295(2008) 4. Michal, M., Giessinger, N., and SchrÖer, R. Reduced thrombus formation in vivo after administration of pentoxifylline (Trental) *Thromb. Res.* 56(3)359-368(1989)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA